- In June 2021, Eisai and Bristol Myers Squibb reached an agreement to work together on the creation and marketing of MORAb-202, Eisai's ADC for advanced solid tumours
- In June 2021, EOS-448, an anti-TIGIT monoclonal antibody that had previously been approved in phase 1 for advanced solid malignancies, was created through a partnership between GSK and iTeos Therapeutics
